PACIRA BIOSCIENCES, INC. Convertible Debt, Noncurrent
PACIRA BIOSCIENCES, INC. (PCRX) had Convertible Debt, Noncurrent of $280.27 million as of 2025-06-30, per its 10-Q filed 2025-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt, Excluding Current Maturities
us-gaap:ConvertibleDebtNoncurrent · last filed 2025-08-05
- 2025-06-30: Convertible Debt, Noncurrent $280.27M.
- 2025-03-31: Convertible Debt, Noncurrent $279.80M.
- 2024-12-31: Convertible Debt, Noncurrent $279.33M.
- 2024-09-30: Convertible Debt, Noncurrent $278.87M.
| Period end | Convertible Debt, Noncurrent |
|---|---|
| 2025-06-30 | $280.27M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $279.80M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $279.33M 10-Q · filed 2025-08-05 |
| 2024-09-30 | $278.87M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $479.55M 10-Q · filed 2024-07-30 |
| 2024-03-31 | $399.21M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $398.59M 10-K · filed 2025-02-27 |
| 2023-09-30 | $397.98M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $397.36M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $405.38M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $404.77M 10-K · filed 2024-02-29 |
| 2022-09-30 | $404.15M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $403.53M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $402.92M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $339.27M 10-K · filed 2023-02-28 |
| 2021-09-30 | $326.15M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $321.71M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $317.34M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $313.03M 10-K · filed 2022-02-28 |
| 2020-09-30 | $456.46M 10-Q · filed 2020-10-30 |
| 2020-06-30 | $314.18M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $310.08M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $306.05M 10-K · filed 2021-03-01 |
| 2019-09-30 | $302.08M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $298.19M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $294.36M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $290.59M 10-K · filed 2020-02-21 |
| 2018-09-30 | $286.89M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $283.26M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $279.69M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $276.17M 10-K · filed 2019-02-28 |
| 2017-09-30 | $272.72M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $269.33M 10-Q · filed 2017-08-02 |
| 2017-03-31 | $265.99M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $108.74M 10-K · filed 2018-02-28 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |